CD4 and myeloid sarcoma: Similarly, investigations on CD4+ T cells from MS patients and control subjects revealed a significant functional implication for TIM-3 expression in CD4+ T cell IFN-γ production; however, unlike in control subjects, monoclonal antibody (mAb)-mediated TIM-3 blockade did not result in increased IFN-γ production in CD4+ T cells from MS patients.